Luckwel Pharmaceuticals Inc.
LWEL
Other OTC3.50
USD
- -
- -
CIK
0001567098
ISIN
US54959L1017
CUSIP
54959L101
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 125 Cambridge Park Drive Cambridge MA United States of America 02140
- IPO Date
- May 20, 2015
- CIK
- 0001567098
- Website
- luckwel.com
- Similar Companies
- Business
- Luckwel Pharmaceuticals Inc. (OTC: LWEL) operates as a specialty pharmaceutical company focused on the acquisition, development, manufacture, and commercialization of innovative therapies targeting autoimmune diseases, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), and infectious diseases; its pipeline includes LWEL-2120 for rheumatoid arthritis, LWEL-2119 for HIV, and LWEL-2103 for COVID-19. The company, founded in 2013 and headquartered in Cambridge, Massachusetts, maintains a lean structure with one employee and limited current operations as a development-stage entity. In April 2018, Luckwel changed its name from Luckycom Pharmaceuticals Inc. to reflect its sharpened focus on pharmaceutical innovation, marking its most recent significant reorganization with no major acquisitions, partnerships, funding rounds, or new product launches reported in the last two years.